Santhera Pharmaceuticals Duchenne Drug Development Update

March 22nd, 2021

March 24:
Santhera Pharmaceuticals Duchenne Drug Development Update – Vamorolone in Duchenne muscular dystrophy

Parent Project Muscular Dystrophy and Santhera Pharmaceuticals are holding a webinar on Wednesday, March 24 at 1 PM (USA Eastern Daylight Time – 5pm Irish time). Santhera will provide an update to the community about the investigational therapy vamorolone, the use of steroids to treat Duchenne muscular dystrophy, clinical trials for vamorolone, and development timelines.

Moderators:

  • Rachel Schrader MS, APRN, CPNP-PC
    Vice President, Clinical Care and Education
    Parent Project Muscular Dystrophy

Presenters:

  • Shabir Hasham, MD
    Vamorolone Global Program Leader
    Santhera Pharmaceuticals
  • Jodi Wolff, PhD
    Head of Global Patient Advocacy
    Santhera Pharmaceuticals

Please submit questions in advance to info@parentprojectmd.org (subject line: Santhera Webinar) by Monday, March 22 at 12 PM EDT.

Register

Share Now:

Categories: Information

Muscular Dystrophy Society of Ireland Ltd.
75 Lucan Road, Chapelizod, Dublin D20 DR77
Fax: (01) 6208663

Registered Charity Number: 20012038
CHY Charity Number: 6849
Company Number: 60460
Country of registration: Ireland

1. Muscular Dystrophies

  • Becker muscular dystrophy
  • Duchenne muscular dystrophy
  • Manifesting carrier of Duchenne
  • Congenital muscular dystrophy
  •     •  General
  •     •  MDC1A (merosin-deficient congenital muscular dystrophy)
  •     •  Rigid spine syndrome (RSS)
  •     •  Ullrich congenital muscular dystrophies
  •     •  Bethlem myopathy
  • Emery-Dreifuss muscular dystrophy
  • Facioscapulohumeral muscular dystrophy
  • Limb-girdle types of muscular dystrophy (LGMD)
  •     •  General
  •     •  LGMD 1B (also known as Laminopathy)
  •     •  LGMD 1C (also known as Caveolinopathy)
  •     •  LGMD 2A (also known as Calpainopathy)
  •     •  LGMD 2B (also known as Dysferlinopathy)
  •     •  LGMD 2I
  • Ocular myopathies including ocularopharangeal muscular dystrophy

2. Myotonic Disorders

  • Congenital Myotonic Dystrophy
  • Myotonia
  • Myotonic Dystrophy

3. Congenital Myopathies

  • Central Core Myopathy
  • Congenital Fibre-type Disproportion Myopathy
  • Minicore (Multicore) myopathy
  • Myotubular or Centronuclear myopathy
  • Nemaline myopathy

4. Mitochondrial Myopathies

  • Mitochondrial Myopathies

5. Metabolic Disorders

  • Metabolic disorders (general)
  • McArdle’s Disease
  • Pompe’s Disease

6. Periodic Paralyses

  • Periodic Paralyses

7. Autoimmune Myositis

  • Polymyositis, Dermatomyositis and Sarcoid myopathy
  • Juvenile dermatomyositis
  • Inclusion body myositis

8. Spinal Muscular Atrophies

  • Severe (Type I)
  • Intermediate (Type II)
  • Mild (Type III)
  • Adult spinal muscular atrophy

9. Hereditary Motor and Sensory Neuropathies

  • (Also known as Charcot-Marie-Tooth or Peroneal muscular atrophy)

10. Disorders of the Neuromuscular Junction

  • Congenital myasthenic syndromes
  • Myasthenia Gravis

11. Friedreich’s Ataxia

  • Friedreich’s Ataxia

12. Other (Please Specify)

13. Unspecified